Tvardi Therapeutics, Inc.
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting STAT3 to treat fibrosis-driven diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 2 clinical development stage for fibrosis-driven diseases with an initial focus on … Read more
Tvardi Therapeutics, Inc. (TVRD) - Total Liabilities
Latest total liabilities as of September 2025: $11.15 Million USD
Based on the latest financial reports, Tvardi Therapeutics, Inc. (TVRD) has total liabilities worth $11.15 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Tvardi Therapeutics, Inc. - Total Liabilities Trend (2020–2024)
This chart illustrates how Tvardi Therapeutics, Inc.'s total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Tvardi Therapeutics, Inc. Competitors by Total Liabilities
The table below lists competitors of Tvardi Therapeutics, Inc. ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
The E W Scripps Co
STU:SQ6B
|
Germany | €4.11 Billion |
|
SeqLL Inc.
PINK:ATLN
|
USA | $119.41 Million |
|
PORT OF TAURANGA LTD ORD
BE:PKF1
|
Germany | €690.55 Million |
|
EHEALTH
BE:M5V
|
Germany | €175.52 Million |
|
KINGFISHER (KFI1.SG)
STU:KFI1
|
Germany | €5.30 Billion |
Liability Composition Analysis (2020–2024)
This chart breaks down Tvardi Therapeutics, Inc.'s total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.48 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.40 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.29 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Tvardi Therapeutics, Inc.'s debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Tvardi Therapeutics, Inc. (2020–2024)
The table below shows the annual total liabilities of Tvardi Therapeutics, Inc. from 2020 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $48.42 Million | -45.63% |
| 2023-12-31 | $89.06 Million | -1.21% |
| 2022-12-31 | $90.15 Million | +361.49% |
| 2021-12-31 | $19.53 Million | -11.83% |
| 2020-12-31 | $22.16 Million | -- |